Inaxaplin APOL1 Kidney Disease — PatSnap Eureka
Inaxaplin & APOL1-Mediated Kidney Disease: The First Genotype-Targeted Renal Therapy
Inaxaplin (VX-147), a small molecule APOL1 inhibitor developed by Vertex Pharmaceuticals, is advancing through the Phase III AMPLITUDE trial as the first genotype-targeted therapy in nephrology — targeting the G1/G2 high-risk variants that drive progressive renal injury in individuals of recent African ancestry.
APOL1 G1/G2 Variants: A Genetically Defined Cause of Progressive Kidney Disease
APOL1-mediated kidney disease (AMKD) is a genetically defined form of progressive renal injury that disproportionately affects individuals of recent African ancestry. The disease is driven by high-risk variants — designated G1 and G2 — in the apolipoprotein L1 (APOL1) gene. Carriers of these variants face substantially elevated risk of focal segmental glomerulosclerosis (FSGS) and related proteinuric kidney diseases, conditions that can progress relentlessly to end-stage renal failure.
The APOL1 protein functions as an ion channel in podocytes — the specialised epithelial cells that form the kidney's filtration barrier. G1 and G2 variants alter APOL1's channel activity, triggering a cascade of podocyte injury, proteinuria, and glomerular scarring. This mechanistic clarity is what makes APOL1 a tractable pharmacological target: if the aberrant channel activity can be inhibited, the downstream injury cascade may be interrupted.
Until recently, nephrology lacked any genotype-targeted therapy. Patients with APOL1-associated FSGS were managed with the same non-specific immunosuppressive and supportive regimens used across all proteinuric kidney diseases, with limited efficacy for this genetically distinct population. The identification of APOL1 as a druggable target — and the subsequent development of small molecule inhibitors — represents a fundamental shift in the therapeutic paradigm for this disease. Learn more about PatSnap's life sciences intelligence platform for tracking such emerging drug targets.
APOL1 Inhibition: Pathway, Modality & Clinical Progression
Understanding the mechanistic and translational landscape of inaxaplin and APOL1-targeted therapy in nephrology.
APOL1 G1/G2 Variant → Disease Pathway Stages
Four mechanistic stages from genotype to end-organ damage, with inaxaplin targeting the APOL1 protein at stage two to interrupt downstream injury.
Inaxaplin (VX-147) Clinical Development Timeline
Progression of inaxaplin from APOL1 target identification through Phase II proof-of-concept to the Phase III AMPLITUDE trial — the first genotype-targeted nephrology programme.
Why Inaxaplin Represents a Paradigm Shift in Nephrology
Four dimensions that define the significance of APOL1-targeted therapy and the inaxaplin programme.
Small Molecule APOL1 Inhibition
Inaxaplin (VX-147) is a small molecule inhibitor that directly targets the APOL1 protein. Unlike biologics, small molecules offer oral bioavailability and the potential to reach intracellular targets — critical advantages for a protein expressed in podocytes. The patent analytics around APOL1 small molecule inhibitors represent a rapidly evolving IP space.
Small molecule · Oral route · Intracellular targetFirst Genotype-Defined Trial in Nephrology
The AMPLITUDE Phase III trial is the first nephrology trial to enrol patients based on a defined genetic variant — APOL1 G1/G2 — rather than a clinical diagnosis alone. This mirrors the oncology model of biomarker-driven patient selection and represents a foundational advance for precision medicine in kidney disease. The APOL1 genotype is the key eligibility criterion.
Genotype-selected · APOL1 G1/G2 · Precision nephrologyAddressing Disproportionate Renal Burden in African Ancestry Populations
APOL1-mediated kidney disease disproportionately affects individuals of recent African ancestry who carry the G1/G2 high-risk variants. This population has historically been underserved by renal therapeutics, making inaxaplin's genotype-targeted approach not only scientifically novel but also a matter of health equity. PatSnap customers in biopharma use Eureka to track equity-relevant pipeline developments.
African ancestry · Health equity · Underserved populationVertex Pharmaceuticals: Lead Assignee in APOL1 Inhibition
Vertex Pharmaceuticals is the primary developer and key assignee in the inaxaplin/VX-147 programme. The APOL1 nephropathy IP landscape encompasses molecular target claims, small molecule inhibitor structures, and clinical method patents. Use PatSnap Eureka to map the full assignee landscape and identify freedom-to-operate risks in this emerging therapeutic space.
Vertex Pharmaceuticals · APOL1 IP · Nephropathy patentsKey Strategic Signals from the Inaxaplin Programme
What the AMPLITUDE trial design and APOL1 targeting strategy signal for the broader nephrology pipeline.
Genotype as Inclusion Criterion
AMPLITUDE's use of APOL1 G1/G2 genotype as a primary inclusion criterion establishes a new precedent in nephrology trial design — shifting from phenotypic diagnosis to molecular patient stratification, directly analogous to oncology's biomarker-driven approach.
APOL1 as a Tractable Pharmacological Target
The advancement of inaxaplin into Phase III validates APOL1 as a druggable target in kidney disease. The protein's ion channel function in podocytes provides a mechanistically defined intervention point that small molecule chemistry can address — a finding with broad implications for the FSGS and chronic kidney disease pipeline.
APOL1-Targeted Approaches: Therapeutic Modality Overview
Comparing the key therapeutic modalities relevant to APOL1-mediated kidney disease and the rationale for small molecule inhibition.
| Therapeutic Modality | Mechanism of Action | Relevance to AMKD | Key Consideration |
|---|---|---|---|
| Small molecule inhibitor (inaxaplin) | Direct APOL1 protein inhibition — blocks aberrant ion channel activity in podocytes | Primary modality — VX-147 in Phase III AMPLITUDE | Oral bioavailability; intracellular target access; genotype-selected patient population |
| Gene silencing (siRNA/ASO) | Knockdown of APOL1 mRNA to reduce protein expression | Preclinical/early clinical exploration for APOL1 reduction | Delivery to kidney podocytes; durability of silencing; off-target effects |
| Non-specific immunosuppression | Broad immune modulation (steroids, calcineurin inhibitors) | Current standard of care for FSGS — not genotype-targeted | Limited efficacy in APOL1 high-risk FSGS; significant toxicity burden |
| RAAS blockade (ACEi/ARB) | Renin-angiotensin-aldosterone system inhibition — reduces proteinuria | Supportive therapy — addresses proteinuria but not APOL1 mechanism | Does not target the genetic driver; used as background therapy in AMPLITUDE |
Track Emerging APOL1 Therapeutic Modalities in Real Time
PatSnap Eureka surfaces new patent filings, clinical signals, and competitor moves across all APOL1-targeted modalities.
Inaxaplin & APOL1-Mediated Kidney Disease — Key Questions Answered
APOL1-mediated kidney disease (AMKD) is a genetically defined form of progressive renal injury that disproportionately affects individuals of recent African ancestry who carry high-risk variants (G1/G2) in the apolipoprotein L1 gene. It is associated with focal segmental glomerulosclerosis (FSGS) and related proteinuric kidney diseases.
Inaxaplin (VX-147) is a small molecule APOL1 inhibitor developed by Vertex Pharmaceuticals. It is designed to pharmacologically target the APOL1 protein and represents the first genotype-targeted therapy advancing in nephrology, currently being evaluated in the Phase III AMPLITUDE trial.
AMPLITUDE is the Phase III clinical trial evaluating inaxaplin (VX-147) for APOL1-mediated kidney disease. It is positioned as the first genotype-targeted therapy trial in nephrology, focusing on patients who carry the high-risk G1/G2 APOL1 variants and present with focal segmental glomerulosclerosis or related proteinuric kidney disease.
The G1 and G2 high-risk variants in the apolipoprotein L1 (APOL1) gene are associated with a genetically defined form of progressive renal injury. Individuals of recent African ancestry who carry these variants face disproportionate risk of APOL1-mediated kidney disease, including FSGS and related proteinuric conditions, making APOL1 genotype a key determinant of disease susceptibility and a pharmacological target.
Inaxaplin is a small molecule inhibitor targeting the APOL1 protein. It represents a genotype-targeted pharmacological approach to renal therapy, positioning APOL1 as a tractable drug target in focal segmental glomerulosclerosis (FSGS) and related proteinuric kidney diseases.
Inaxaplin (VX-147) is developed by Vertex Pharmaceuticals. The compound is the lead asset in Vertex's APOL1-targeted nephrology program. The broader IP landscape around APOL1 inhibition in kidney disease — including patent assignees, molecular target claims, and translational signals — can be explored using PatSnap Eureka's innovation intelligence platform.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About APOL1 & InaxaplinAccelerate Your APOL1 & Nephrology Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track genotype-targeted therapies, map IP landscapes, and identify pipeline opportunities in rare and precision kidney disease.
References
- NCBI Gene — APOL1 Apolipoprotein L1 Gene Record
- Nature — Ion Channels: Research and Review Collection
- National Human Genome Research Institute — APOL1 Genetics Glossary
- National Kidney Foundation — Focal Segmental Glomerulosclerosis (FSGS)
- ClinicalTrials.gov — AMPLITUDE Phase III Trial (VX-147 / Inaxaplin)
- PatSnap — Life Sciences Innovation Intelligence Platform
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.